What is the 13F Pro Quality Score for NBIX?

13F Pro ranks NEUROCRINE BIOSCIENCES INC (NBIX) on the 13F Pro Quality Score, a 0–100 composite of 32 fundamental signals including return on invested capital, free cash flow consistency, balance-sheet strength, earnings quality, growth durability, and valuation discipline. The score refreshes after each 10-K and 10-Q filing on SEC EDGAR. View NBIX's current score at https://13fpro.ai/company/NBIX (free sign-up required for the full ranking).

Which hedge funds own the most NBIX stock?

Based on the most recent Form 13F-HR filings on SEC EDGAR, the largest reported institutional holders of NBIX include BlackRock,, JPMORGAN CHASE & CO, DODGE & COX. Holdings are reported quarterly within 45 days of quarter-end and updated on https://13fpro.ai/company/NBIX as soon as new 13F filings post.

Where does 13F Pro source NBIX data?

All NEUROCRINE BIOSCIENCES INC fundamentals and ownership data come directly from SEC EDGAR. NEUROCRINE BIOSCIENCES INC files with the SEC under CIK 914475. 13F Pro ingests XBRL financial facts from 10-K and 10-Q filings, Form 13F-HR institutional holdings, and Form 4 insider transactions, with no third-party rewrites or estimates.

What sector is NBIX in?

NEUROCRINE BIOSCIENCES INC (NBIX) is classified in the Healthcare sector. 13F Pro publishes sector-level fund flow analysis and quality leaders at https://13fpro.ai/research/sector/healthcare.

What drives NBIX's revenue?

Per NEUROCRINE BIOSCIENCES INC's latest 10-Q filed with the SEC on 2026-07-31, the biggest revenue drivers are: INGREZZA net product sales ($716.5M); CRENESSITY net product sales ($183.5M); VYKAT XR net product sales ($54.3M). Figures are extracted from the filing text and machine-verified against the document. Full breakdown at https://13fpro.ai/company/NBIX.

What are NBIX's largest expenses?

NEUROCRINE BIOSCIENCES INC's latest 10-Q reports these as the largest expense items: Selling, general, and administrative ($439.7M, 45.8% of total revenues vs 41.6%); Research and development ($326.7M, 34.1% of total revenues vs 35.5%); Cost of revenues, excluding amortization of acquired intangible assets ($23.2M, 2.4% of total revenues vs 1.6%). Sourced directly from SEC EDGAR filing text for Q2 FY2026 (quarter ended June 30, 2026).

How often is NBIX research updated on 13F Pro?

NBIX's fundamentals refresh within hours of each new 10-K or 10-Q filing on SEC EDGAR. Institutional ownership updates after each quarterly 13F filing window. Insider transactions update after each Form 4 filing. The 13F Pro Quality Score recalculates after every fundamentals refresh.

NEUROCRINE BIOSCIENCES INC(NBIX)Stock Analysis

AI analysis on 2,800+ stocks →Deep AI analysis on 2,800+ stocks →

Healthcare →Nasdaqlarge

Institutional-grade research for retail investors

SEC EDGAR: CIK 914475 NBIX stock profile & AI dashboard →

13F Pro Quality Score

76.5/100

Rank #83 of 2,961 stocksTOP 5%

View Healthcare peers →

Rankings refresh quarterly once 80% of peers have filed (~45 days after quarter-end). Next update: ~Nov 14, 2026.

Revenue Growth

86.7/100

Profitability

85.1/100

Balance Sheet

93.0/100

Earnings Quality

68.5/100

Free Cash Flow

79.6/100

Institutional Flow

42.5/100

Revenue Scale

71.9/100

Dilution Risk

19.6/100

Email me the moment this company reports earnings

AI Research Report

Two-page plain-English analysis: business, thesis, and three scenarios for the next two years. Refreshed every quarter.

Upgrade to Pro

Pro: 5 reports/month · Pro+: unlimitedOpinion, not investment advice. Do your own research.

Why NBIX Scores 77/100

exact factor attribution · 2026-09-11

NBIX's composite is driven by revenue growth and profitability, held back by shareholder dilution. Bars show each factor's exact push vs. a median company, using the same weights the ranking engine applies.

Revenue growth

+7.3 pts

87th pct

Profitability

+5.3 pts

85th pct

Free cash flow

+4.4 pts

80th pct

Capital efficiency

+4.3 pts

93th pct

Scale

+3.3 pts

72th pct

Earnings growth

+1.9 pts

89th pct

Earnings quality

+1.9 pts

69th pct

Institutional flow

-0.4 pts

43th pct

Shareholder dilution

-1.5 pts

20th pct

Latest change (2026-07-31): 75 → 74 · ↓ Revenue growth 84→72; ↓ Earnings growth 92→72

Factor percentiles are cross-sectional ranks across the ~2,800-stock scored universe, computed from SEC EDGAR filings. Not investment advice.

NBIX Stock Analysis & AI Quality Score

Data updated 2026-09-11

AI stock analysis and institutional research for NEUROCRINE BIOSCIENCES INC (NBIX), a Healthcare sector company. 13F Pro's AI-powered ranking engine scores NBIX at 76.5/100 on a 32-signal composite quality model, placing it at rank #83 of 2,961 stocks — the top 5% of the AI-ranked universe. NBIX scores in the top quartile across balance sheet strength (93.0), revenue growth (86.7), profitability (85.1). Shareholder dilution risk is elevated at 19.6/100, reflecting ongoing share issuance or stock-based compensation. Based on the latest XBRL financial filings (Q2 2026), NEUROCRINE BIOSCIENCES INC reports quarterly revenue of $959.0M, net income of $144.4M, free cash flow of $128.6M. Top institutional holders of NBIX by reported 13-F value include BlackRock, JPMORGAN CHASE, DODGE & COX, based on the most recent SEC filings. NBIX trades on the Nasdaq exchange and files with the SEC under CIK 914475. 13F Pro's AI research platform runs 10 specialized AI analysts — value, growth, momentum, macro, and activist specialists — that debate NBIX daily and publish AI-generated analysis with cited SEC sources. The platform aggregates historical XBRL financial facts, 10-Q and 10-K filings, insider Form 4 transactions, and institutional 13-F holdings for NEUROCRINE BIOSCIENCES INC directly from SEC EDGAR. NEUROCRINE BIOSCIENCES INC's 13F Pro composite quality score has ranged between 46 and 81 since 2021, currently 76.5 — a declining long-term trajectory across 68 quarterly and live scoring snapshots.

✦

Fun facts about NEUROCRINE BIOSCIENCES INC

Quirks, history, and lore behind NBIX — the kind of stuff that makes a stock memorable.

1
The Basics
U.S. biopharmaceutical company · mid-cap · listed on Nasdaq · headquartered in San Diego, California.
2
The Numbers
Annual revenue in the range of roughly $2 billion, driven almost entirely by a single blockbuster drug — a rare feat of focus in an industry that loves sprawl.
3
The History
Founded in the mid-1990s, it spent years as a quiet CNS-focused biotech before a landmark deal with AbbVie helped fund its early pipeline and put it on the map.
4
The Secret
Its core expertise is in neurological and psychiatric disorders — the kind of conditions that Big Pharma long ignored — including tardive dyskinesia and movement disorders.
5
The Lore
Its top-selling drug Ingrezza (valbenazine) was the first FDA-approved treatment specifically for tardive dyskinesia, a condition affecting millions who had been largely left behind by medicine.
6
The Giveaway
Ticker NBIX, built on Ingrezza, and quietly becoming one of neuroscience's most focused success stories — this is Neurocrine Biosciences.

▶ Think you know your stocks? Play the Daily Ticker

What's Driving NBIX's Business? Latest 10-Q Breakdown

✓ 32/32 datapoints verified

AI-extracted from NEUROCRINE BIOSCIENCES INC's 10-Q filed 2026-07-31 — Q2 FY2026 (quarter ended June 30, 2026). Every figure is machine-verified against the filing text on SEC EDGAR.

Q2 revenue reached $959.0 million as CRENESSITY scaled to $183.5 million and newly acquired VYKAT XR added $54.3 million, but operating income rose only to $151.5 million on $2.83 billion Soleno deal costs.

Biggest Revenue Drivers

INGREZZA net product sales$716.5M

Volume growth in total prescriptions and record new prescriptions on strong patient demand

CRENESSITY net product sales$183.5M

Launched in the U.S. December 2024 as first-in-class FDA-approved treatment of classic CAH

Biggest Revenue Drivers

Total revenue: $959.0M

INGREZZA net product sales$716.5M

Volume growth in total prescriptions and record new prescriptions on strong patient demand

CRENESSITY net product sales$183.5M

Launched in the U.S. December 2024 as first-in-class FDA-approved treatment of classic CAH

VYKAT XR net product sales$54.3M

Inclusion of VYKAT XR sales following the acquisition of Soleno in May 2026

Other revenues$4.7M

Primarily royalties on AbbVie net sales of elagolix and Tanabe Pharma net sales of valbenazine

Largest Expense Items

Selling, general, and administrative$439.7M45.8% of total revenues vs 41.6%

Continued commercial investment plus $96.8M acquisition-related expenses, including $40.2M stock-based compensation on accelerated Soleno awards

Research and development$326.7M34.1% of total revenues vs 35.5%

Progression of Phase 3 programs for osavampator in MDD and direclidine in schizophrenia; higher headcount

Cost of revenues, excluding amortization of acquired intangible assets$23.2M2.4% of total revenues vs 1.6%

Higher net product sales, CRENESSITY royalties, $3.0M VYKAT XR inventory fair-value step-up amortization and $2.0M acquisition-related expenses

Amortization of acquired intangible assets$16.4M1.7% of total revenues vs 0.1%

Amortization of the $2.24 billion VYKAT XR developed product rights acquired with Soleno, over a 16-year useful life

Margins: Cost of revenues rose to 2.4% of revenues from 1.6%, and SG&A to 45.8% from 41.6% on Soleno deal costs; R&D eased to 34.1% from 35.5%.

Watch Items from the Filing

Customer concentration: Customers A, B and C were 34%, 26% and 28% of gross product sales; four customers exceed 90% of total gross product sales.
Liquidity fell to $481.7 million of cash and marketable securities from $2,543.4 million, after $2.36 billion net cash paid for Soleno.
August 2025 DOJ civil investigative demand on INGREZZA sales and marketing remains open; Zydus filed an ANDA with Paragraph IV certification against INGREZZA SPRINKLE.
Acquired VYKAT XR inventory step-ups of $41.5M (WIP) and $126.7M (finished goods) will burden cost of revenues over roughly four to six years.
Effective tax rate fell to 11.0% from 32.6%, aided by a discrete benefit from releasing part of a state deferred tax valuation allowance.

AI-extracted and verified against SEC EDGAR filing text. Not investment advice.

Read the full 10-Q on SEC EDGAR →Share on X

Revenue

Q2 2026

$959.0M

Net Income

Q2 2026

$144.4M

Free Cash Flow

Q2 2026

$128.6M

ROIC

Q2 2026

16.4%

Period

Revenue & Net Income

Earnings Per Share

Key Financials Over Time

Export Financial Table · Pro

Revenue

+21.4% YoY

$2.86BFY 2025

FY22 $1.49BFY23 $1.89BFY24 $2.36BFY25 $2.86B

Net Income

+40.2% YoY

$478.6MFY 2025

FY22 $154.5MFY23 $249.7MFY24 $341.3MFY25 $478.6M

Operating Income

+8.5% YoY

$619.1MFY 2025

FY22 $249.0MFY23 $250.9MFY24 $570.5MFY25 $619.1M

EPS (Diluted)

+41.9% YoY

$4.67FY 2025

FY22 $1.56FY23 $2.47FY24 $3.29FY25 $4.67

Total Assets

+24.5% YoY

$4.63BFY 2025

FY22 $2.37BFY23 $3.25BFY24 $3.72BFY25 $4.63B

Op. Cash Flow

+31.5% YoY

$782.7MFY 2025

FY22 $339.4MFY23 $389.9MFY24 $595.4MFY25 $782.7M

Free Cash Flow

+34.4% YoY

$748.7MFY 2025

FY22 $322.9MFY23 $361.6MFY24 $557.2MFY25 $748.7M

Metric	FY 2025	FY 2024	FY 2023	FY 2022	FY 2021	FY 2020
Revenue	$2.86B +21.4%	$2.36B +24.8%	$1.89B +26.8%	$1.49B +31.3%	$1.13B +8.4%	$1.05B
Net Income	$478.6M +40.2%	$341.3M +36.7%	$249.7M +61.6%	$154.5M +72.4%	$89.6M -78.0%	$407.3M
Operating Income	$619.1M +8.5%	$570.5M +127.4%	$250.9M +0.8%	$249.0M +142.9%	$102.5M -37.1%	$163.0M
EPS (Diluted)	$4.67 +41.9%	$3.29 +33.2%	$2.47 +58.3%	$1.56 +69.6%	$0.92 -77.9%	$4.16
Total Assets	$4.63B +24.5%	$3.72B +14.4%	$3.25B +37.3%	$2.37B +14.3%	$2.07B +19.5%	$1.73B
Operating Cash Flow	$782.7M +31.5%	$595.4M +52.7%	$389.9M +14.9%	$339.4M +32.3%	$256.5M +12.3%	$228.5M
Free Cash Flow	$748.7M +34.4%	$557.2M +54.1%	$361.6M +12.0%	$322.9M +38.5%	$233.1M +7.1%	$217.6M

Get alerted when NBIX's score changes

Free account: watchlist tracking, the daily AI brief, and the AI screener.

Passwordless sign-in · Payments by Stripe · Auth by Clerk

Available Research

13F Pro tracks comprehensive data for NEUROCRINE BIOSCIENCES INC including:

SEC EDGAR filings (10-K, 10-Q, 8-K)

XBRL financial facts (revenue, EPS, margins)

Insider transactions (Form 4)

Institutional 13F holdings

Quality rankings (32 signals)

AI analyst debates & daily meetings

Historical financial trends

Peer comparison & sector analysis

Top Institutional Holders of NBIX

BlackRock, Inc.
$2.3B13,711,607 sh
JPMORGAN CHASE & CO
$1.1B6,398,674 sh
DODGE & COX
$941.2M5,584,707 sh
VANGUARD PORTFOLIO MANAGEMENT LLC
$838.3M4,974,083 sh
VANGUARD CAPITAL MANAGEMENT LLC
$766.0M4,545,339 sh
STATE STREET CORP
$739.1M4,385,598 sh
AQR CAPITAL MANAGEMENT LLC
$643.5M3,818,037 sh
RENAISSANCE TECHNOLOGIES LLC
$393.7M2,335,897 sh
GEODE CAPITAL MANAGEMENT, LLC
$359.6M2,138,777 sh
TWO SIGMA INVESTMENTS, LP
$349.9M2,076,260 sh

Fund	Value	Shares
BlackRock, Inc.	$2.3B	13,711,607
JPMORGAN CHASE & CO	$1.1B	6,398,674
DODGE & COX	$941.2M	5,584,707
VANGUARD PORTFOLIO MANAGEMENT LLC	$838.3M	4,974,083
VANGUARD CAPITAL MANAGEMENT LLC	$766.0M	4,545,339
STATE STREET CORP	$739.1M	4,385,598
AQR CAPITAL MANAGEMENT LLC	$643.5M	3,818,037
RENAISSANCE TECHNOLOGIES LLC	$393.7M	2,335,897
GEODE CAPITAL MANAGEMENT, LLC	$359.6M	2,138,777
TWO SIGMA INVESTMENTS, LP	$349.9M	2,076,260

Companies Similar to NBIX

Ranked by quality-profile closeness and shared hedge-fund ownership — not just sector membership.

INCY

INCYTE CORP

AI score

Very similar · 44 shared holders

DODGE & COX CAISSE DE DEPOT ET PLACEMENT DU QUEBEC ARMISTICE CAPITAL, LLC

EXEL

EXELIXIS, INC.

AI score

Very similar · 28 shared holders

CAISSE DE DEPOT ET PLACEMENT DU QUEBEC Swedbank AB FULLER & THALER ASSET MANAGEMENT, INC.

BSX

BOSTON SCIENTIFIC CORP

AI score

Very similar · 28 shared holders

CAISSE DE DEPOT ET PLACEMENT DU QUEBEC PRIMECAP MANAGEMENT CO/CA/NORDEA INVESTMENT MANAGEMENT AB

UTHR

UNITED THERAPEUTICS Corp

AI score

Very similar · 37 shared holders

Vestal Point Capital, LP Swedbank AB CAISSE DE DEPOT ET PLACEMENT DU QUEBEC

DXCM

DEXCOM INC

AI score

Very similar · 31 shared holders

Swedbank AB Korea Investment CORP Bridgewater Associates, LP

RMD

RESMED INC

AI score

Very similar · 30 shared holders

Swedbank AB CAISSE DE DEPOT ET PLACEMENT DU QUEBEC AustralianSuper Pty Ltd

PODD

INSULET CORP

AI score

Very similar · 39 shared holders

Vestal Point Capital, LP Vinva Investment Management Ltd NORDEA INVESTMENT MANAGEMENT AB

KRYS

Krystal Biotech, Inc.

AI score

Similar quality profile · 24 shared holders

Hood River Capital Management LLC BRAIDWELL LP C WorldWide Group Holding A/S

Similarity is computed from the 8 composite sub-scores and latest-quarter 13F conviction holdings (index-style filers excluded). Refreshed monthly.

More Healthcare Companies

View all Healthcare →

AAPG

ASCENTAGE PHARMA GROUP INTERNATIONAL

AARD

Aardvark Therapeutics, Inc.

ABBV

AbbVie Inc.

ABCL

AbCellera Biologics Inc.

ABEO

ABEONA THERAPEUTICS INC.

ABOS

Acumen Pharmaceuticals, Inc.

ABPWW

Abpro Holdings, Inc.

ABSI

Absci Corp

Put NBIX on your watchlist

Track score changes the day NEUROCRINE BIOSCIENCES INC files with the SEC, follow the hedge funds that own it, screen 2,800+ AI-scored stocks, and get the daily brief — free.

View Pricing

Free tier includes 13F data, economic indicators, and market overview. Pro starts at $6.67/mo (billed annually).

Passwordless sign-in · Payments by Stripe · Auth by Clerk

Popular Research

AAPL

Apple

MSFT

Microsoft

NVDA

NVIDIA

GOOG

Alphabet

AMZN

Amazon

Is NBIX a good stock to buy?

13F Pro's AI-powered analysis of NEUROCRINE BIOSCIENCES INC (NBIX) draws on SEC EDGAR-sourced fundamentals, institutional 13F holdings, and insider Form 4 transactions in the Healthcare sector (listed on Nasdaq). The 32-signal AI Quality Score, current rank, and full bull/bear verdict for NBIX are available on the NBIX stock profile dashboard — with the same data, AI insights, ratios, and institutional activity refreshed after every 10-K, 10-Q, 13F, and Form 4 filing. NBIX is classified as a large company.

Which hedge funds own NBIX?

Institutional investors are required to disclose their holdings quarterly via SEC Form 13F. 13F Pro aggregates these filings to show which hedge funds, mutual funds, and asset managers are buying or selling NBIX. Combined with insider transaction data from Form 4 filings and AI-powered analysis from 10 specialized research agents, 13F Pro provides a comprehensive view of NEUROCRINE BIOSCIENCES INC's investment landscape.